Clinical Trials in Obninsk, Russia
12 recruiting
Showing 1–12 of 12 trials
Recruiting
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
Prostate Cancer
AstraZeneca400 enrolled22 locationsNCT07052578
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled175 locationsNCT01804686
Recruiting
An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation
Endometrial Cancer
AstraZeneca500 enrolled21 locationsNCT07041606
Recruiting
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
Bladder Cancer
AstraZeneca600 enrolled22 locationsNCT07038928
Recruiting
Phase 1
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
Metastatic Colorectal Cancer
R-Pharm180 enrolled26 locationsNCT07543744
Recruiting
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia
Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
AstraZeneca2,000 enrolled41 locationsNCT05887011
Recruiting
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation
Prostate Cancer
AstraZeneca400 enrolled17 locationsNCT07146113
Recruiting
Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Cancer
Bayer402 enrolled383 locationsNCT04464226
Recruiting
Phase 2
BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
Triple-Negative Breast Cancer
Biocad124 enrolled47 locationsNCT07108309
Recruiting
Phase 2
OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites
Metastatic Disease
National Medical Research Radiological Centre of the Ministry of Health of Russia50 enrolled1 locationNCT06856603
Recruiting
Phase 2
An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Biocad100 enrolled20 locationsNCT06668792
Recruiting
Phase 2Phase 3
Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care
Oligometastatic Disease
National Medical Research Radiological Centre of the Ministry of Health of Russia100 enrolled1 locationNCT06556550